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Article

Altered Expression of Genes Involved in GABAergic
Transmission and Neuromodulation of Granule Cell
Activity in the Cerebellum of Schizophrenia Patients
W. Michael Bullock
Karen Cardon
Juan Bustillo, M.D.
Rosalinda C. Roberts, Ph.D.
Nora I. Perrone-Bizzozero, Ph.D.

Objective: Deficits in gamma-aminobutyric acid (GABA) signaling have been described in the prefrontal cortex, limbic
system, and cerebellum in individuals
with schizophrenia. The purpose of the
present study was to further investigate
cerebellar gene expression alterations as
they relate to decreases in GABAergic
transmission by examining the expression
of GABAergic markers, N-methyl-D-aspartic-acid (NMDA) receptor subunits, and
cerebellum neuromodulators in individuals with schizophrenia.
Method: Subjects we re postmortem
men with a diagnosis of schizophrenia
(N =1 3) and a postmortem intervalmatched non-psychiatric male comparison group (N=13). The authors utilized
real-time-quantitative polymerase chain
reaction (PCR) to measure mRNA levels of
the following GABAergic markers:
glutamic acid decarboxylase (GAD) 65 and
67; GABA plasma membrane transporter1 (GAT-1); GABA type A (GABA A) receptor
subunits α6, β3, and δ; and parvalbumin.
In addition, real-time-quantitative PCR
was utilized to assess mRNA levels of the
NMDA receptor (NR) subunits NR1, NR2-A,
NR2-B, NR2-C, and NR2-D as well as the
cerebellar neuromodulators glutamate

receptor (GluR)-6, kainate-preferring
glutamate receptor subunit-2 (KA2), metabotropic glutamate receptor (mGluR)-2
and mGluR3, and neuronal nitric oxide
synthase. Measurements for mRNA levels
were determined using lateral cerebellar
hemisphere tissue from both schizophrenia and comparison subjects.
Results: Schizophrenia subjects showed
significant decreases in mRNA levels of
GAD67 , GAD65, GAT-1, mGluR2, and neuronal nitric oxide synthase. Increases in
GABAA-α6 and GABAA-δ as well as GluR6
and KA2 were also observed. Medication
effects on the expression of the same
genes were examined in rats treated with
either haloperidol (Sprague-Dawley rats
[N=16]) or clozapine (Long-Evans rats [N=
20]). Both haloperidol and clozapine increased the levels of GAD67 in the cerebellum and altered the expression of other
cerebellar mRNAs.
Conclusions: These findings suggest that
GABA transmission is decreased in the
cerebellar cortices in individuals with
schizophrenia and additional gene expression changes may reflect an attempt
to increase GABA neurotransmission at
the cerebellar glomerulus.
(Am J Psychiatry Bullock et al.; AiA:1–10)

O

ne of the most consistent molecular findings from
schizophrenia research is the dysfunction of specific subsets of gamma-aminobutyric acid (GABA) expressing interneurons (1–4). Reductions in mRNA and protein levels
of glutamic acid decarboxylase 67 (GAD 67 ) have been
found in specific interneurons of the prefrontal cortex (5–
7) and limbic system in individuals with schizophrenia (8,
9), and similar findings have been observed in analyses of
whole cerebellar tissue (10, 11). The same prefrontal cortex interneurons with GAD67 reductions have also shown
decreases in the presynaptic GABA plasma membrane
transporter-1 (GAT-1) (12). Compensatory postsynaptic
changes, such as increases in GABA type A (GABAA)-α2 receptor density and GABAA receptor radioligand binding,
in the prefrontal cortex and anterior cingulate cortex have
also been reported (13–15). In addition, single nucleotide
AJP In Advance

polymorphisms (SNPs) in the promoter region of the
GAD67 gene expression have been associated with gray
matter reductions in patients with childhood onset
schizophrenia (16) and decreased cognitive functioning in
adult schizophrenia (17). Given the role of GABAergic interneurons in the modulation of excitatory output, dysfunction in specific interneurons may mediate some of
the positive, negative, and cognitive symptoms seen in
schizophrenia.
Aside from its role in motor coordination, the cerebellum has been shown to contribute to cognitive functioning (18) through connections of the posterior lateral
hemispheres to the prefrontal cortex (19). Thus, physiological deficits in this brain region could contribute to the
pathophysiology of schizophrenia. Supporting this hypothesis, neuroimaging studies have described increased
ajp.psychiatryonline.org
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blood flow and glucose consumption in the cerebellum
among schizophrenia patients (20–22). Molecular studies
have revealed decreased cerebellar expression of the
GABAergic protein reelin and the GABA synthesizing enzymes GAD67 and GAD65 (10, 11) as well as increased expression of the axonal chemorepellent Semaphorin 3A
(23) and increased expression of granule cell-selective,
activity-dependent, brain-derived neurotrophic factor,
and growth-associated protein of 43 kDa (GAP-43) genes
(24). To further explore the function of cerebellar interneurons in schizophrenia, we investigated changes in
transcript levels of GABAergic markers, N-methyl-D-aspartate (NMDA) receptor subunits, and local circuit neuromodulators of GABA release using total RNA prepared
from the posterior lateral cerebellar hemispheres of postmortem male schizophrenia subjects and age- and postmortem interval-matched male comparison subjects. Alterations in specific GABAergic transcripts point to a
common pathophysiological mechanism across different
brain regions and implicate the cerebellum in the cognitive and motor dysfunction observed in individuals with
schizophrenia.

Method
Human Subjects
Subjects were postmortem men (N=13) with a diagnosis of
schizophrenia (according to DSM-IV criteria) and a sex-, age-,
and postmortem interval-matched comparison group (N=13).
Cerebellar tissue from both schizophrenia and comparison subjects was acquired from the Maryland Brain Collection (Table 1).
All subjects were between 25 and 65 years of age at the time of
death, with a postmortem interval ≤24 hours. None of the subjects had a history of alcohol abuse or dependence. No significant differences were found between schizophrenia and comparison subjects for the fol lowing factors: 1) mean age
(schizophrenia group: 43.5 years [SD=11], range=31–62 years;
comparison group: 40.9 years [SD=8], range=27–50 years); 2)
mean postmortem interval (schizophrenia group: 12.1 hours
[SD=5.1], range=5–21 hours; comparison group: 16.5 hours [SD=
5.4], range=6–24 hours); 3) mean brain pH (schizophrenia
group: 6.53 [SD=0.2], range=6.21–6.74; comparison group: 6.50
[SD=0.1], range=6.29–6.64); 4) mean RNA integrity number
(schizophrenia group: 7.98 [SD=0.12], range=7.30–8.50; comparison group: 7.73 [SD=0.11], range=7.00–8.60); and 5) mean
freezer storage time (schizophrenia group: 71 months [SD=24],
range=27–157 months; comparison group: 49 months [SD=29],
range=10–100 months). At the time of death, six subjects were
receiving typical antipsychotics and seven were receiving atypical antipsychotics. Neither schizophrenia nor comparison subjects were receiving medications for mood disorders at the time
of death. The subjects’ cerebellar tissue originated from the lateral cerebellar hemisphere corresponding to crus I of lobule
VIIa, which has projections to the prefrontal cortex (19). Specimens were dissected at –20°C and frozen at –80°C until ready for
use.

Haloperidol-Treated Rats
The RNA from the cerebellum of Sprague-Dawley rats (N=16)
treated with haloperidol was acquired from a previous study
(25). The rats were injected (intramuscular) with either haloperidol depot (38 mg/kg/month [corresponding to approxi-
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mately 1 mg/kg/day]) or sesame oil (vehicle [comparison
group]). After a 7-day acclimation period, the rats were injected
once a month for 6 months. They were anesthetized using isoflurane and decapitated 1 month after the last injection. The
cerebellum of each rat was removed intact, frozen on dry ice,
and stored at –80°C.

Clozapine-Treated Rats
Adult male Long-Evans rats (N=20) were injected (intraperitoneal) with either clozapine (10 mg/kg/day), dissolved in 0.4% acetic acid in 0.9% saline, or a vehicle (comparison group) for 21
days. This paradigm was modified from methods described by Bai
et al. (26), which suggested a maximum D2 receptor occupancy
for clozapine. The cerebellum of each rat in both the clozapinetreated group and vehicle-treated comparison group was removed 18 hours after the last injection, and the lateral hemispheres were dissected and frozen at –80°C.

Quantitative Real-Time Polymerase Chain Reaction
(PCR)
All experimental procedures and data analyses were performed
blind to the diagnosis. The cerebellar tissue from both human
and rat subjects was homogenized using a Polytron homogenizer
(Brinkmann Instruments, Westbury, N.Y.). Total RNA was isolated
using TriReagent (Sigma, St. Louis) and analyzed with Bioanalyzer
2100 (Agilent Technologies, Santa Clara, Calif.). As detailed in Table 1, all RNA integrity number values were ≥7.0. The cDNA was
synthesized from 4 µg of the total RNA using MMLV Reverse Transcriptase (Promega, Madison, Wisc.). Real-time-quantitative
PCRs were run via an Applied Biosystems (Foster City, Calif.) 7000,
7300, or 7500 fast-quantitative real-time PCR machine. Gene expression levels for all human tissue samples as well as those for
tissue samples of neuroleptic-treated rats were examined using
SYBR Green (Applied Biosystems, Foster City, Calif.), with the exception of the GABAergic markers GABAA-α6 and GABAA-δ, which
were analyzed via TaqMan Assays-on-Demand probes (Applied
Biosystems, Foster City, Calif.). All gene expression levels were examined according to the manufacturers’ protocols. Exon spanning primer pairs (Operon, Huntsville, Ala.) specific to 1) GABAergic markers GABAA-β3, GAD67, GAD65, parvalbumin, and GAT-1;
2) NMDA receptor (NR) subunits NR1, NR2-A, NR2-B, NR2-C, and
NR2-D; and 3) cerebellar neuromodulators metabotropic
glutamate receptor (mGluR)-2 and mGluR3, kainate-preferring
glutamate receptors GluR6 and KA2, and neuronal nitric oxide
synthase were designed using Primer Express 3.0 (Applied Biosystems, Foster City, Calif. [see the table in the data supplement accompanying the online version of this article]). Expression levels
of genes of interest were normalized to those of β-actin, and expression levels were reconfirmed using cyclophilin for selected
genes. Validation curves for all primer sets were run with housekeeping genes and shown to have a linear slope of <|0.1|. Dissociation curves for all SYBR Green primer sets showed no evidence
of dimerization.

Data and Statistical Analysis
Cerebellar tissue samples from the 13 schizophrenia subjects
and 13 comparison subjects were run in triplicate in three separate plates and compared with β-actin or cyclophilin on the
same plate. The relative levels of expression of each mRNA were
corrected by housekeeping genes according to a previously described method (24), and the relative GABAergic transcript levels for schizophrenia subjects versus comparison subjects were
calculated using the 2–∆∆ct method (27). The averaged values per
tissue sample were entered into Prism 4.0 (GraphPad Software,
San Diego) and analyzed using the Wilcoxon Signed-Rank Test
for pair-matched human subjects and Student’s t tests for rats.
For further analysis of human subjects, SSPS 15.0 for Windows
AJP In Advance
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TABLE 1. Demographic and Clinical Characteristics of Postmortem Male Schizophrenia Subjects and Age- and Postmortem
Interval-Matched Male Comparison Subjects
Postmortem Status for Schizophrenia (N=13) and Comparison (N=13) Subjects
Matched Subject
Pairsa
Codeb
Schizophrenia
subjects
1
42a

Race

Antipsychotic
Cerebellar Tissue
Freezer Storage Treatment at the
Time of Death
Time (months)

Age
(years)

Postmortem
Interval
(hours)

Brain pH

RNA
Integrity
Number

33

12

6.21

7.40

28

Olanzapine

Appendicitis

31

14

6.74

8.30

104

Clozapine

32
37
38

7
14
6

6.58
6.68
6.22

8.00
7.30
7.80

99
27
69

Clozapine
Risperidone
Fluphenazine

Arteriosclerotic
cardiovascular disease
Suicide
Suicide
Asphyxia

38

5

6.64

8.50

157

Chlorpromazine

Pneumonia

Cause of Death

2

39∗

3
4
5

7s
41
3s

6

11s

7

5s

8
9

18
31

African
American
African
American
Caucasian
Caucasian
African
American
African
American
African
American
Caucasian
Caucasian

10
11
12

5
36
1s

Caucasian
Caucasian
Caucasian

49
59
53

16
13
11

6.55
6.67
6.69

7.50
8.40
7.90

78
64
58

Thioridazine
Haloperidol
Perphenazine

13

1

African
American

62

12

6.56

8.00

55

Olanzapine

Comparison
subjects
1

35

33

14

6.50

8.60

81

Morbid obesity

2

8s

27

14

6.56

7.80

10

Asthma

3
4

12s
34∗

African
American
African
American
Caucasian
Caucasian

31
35

16
16

6.61
6.44

7.80
7.70

12
23

5
6

4s
4∗

Polytrauma
Arteriosclerotic
cardiovascular disease
Asphyxia
Cardiomyopathy

7

42

21

6.25

7.80

71

Perphenazine

Tuberculosis

45
46

6
20

6.65
6.42

8.40
8.50

56
52

Olanzapine
Olanzapine

Suicide
Arteriosclerotic
cardiovascular disease
Intoxication
Embolism
Arteriosclerotic
cardiovascular disease
Arteriosclerotic
cardiovascular disease

38
38

24
12

6.55
6.50

7.70
7.50

46
100

40

Caucasian
African
American
Caucasian

43

20

6.29

7.50

69

8

12

Caucasian

47

6

6.46

8.30

80

9
10
11
12

10s
6s
17
21∗

Caucasian
Caucasian
Caucasian
Caucasian

46
47
48
49

24
17
19
10

6.64
6.52
6.51
6.49

7.00
7.50
8.00
7.30

15
20
79
79

13

2s

Caucasian

50

22

6.38

7.80

23

a Pairs matched according to age
b Maryland Brain Collection code

and postmortem interval.
numbers for schizophrenia and comparison subjects. Asterisk marks are part of the code number.

(SPSS, Chicago) was employed, which included analyses of covariance (ANCOVA) to determine the effect of age, postmortem
interval, brain pH, RNA integrity number, and freezer storage
time at the levels of each GABAergic transcript. Initial analyses
demonstrated no significant effects of brain pH and postmortem interval at the levels of any of the transcripts. Thus, for all
subsequent analyses, diagnosis was used as the independent
variable, and age, RNA integrity number, and freezer storage
time were used as covariates. A bivariate Spearman’s r correlation analysis was employed to examine putative gene-gene interactions. Any statistical analysis with a p value <0.05 was considered significant.
AJP In Advance

Arteriosclerotic
cardiovascular disease
Arteriosclerotic
cardiovascular disease
Arrhythmia
Arrhythmia
Aneurysm
Arteriosclerotic
cardiovascular disease
Arteriosclerotic
cardiovascular disease

Results
GABAergic Marker Expression in the Lateral
Cerebellar Hemisphere of Schizophrenia
Subjects
Given the evidence of GABA dysfunction among individuals with schizophrenia, we sought to characterize the
condition of inhibitory interneurons in the cerebellum of
schizophrenia subjects in order to 1) investigate the mechanisms underlying cerebellar abnormalities and 2) examajp.psychiatryonline.org
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TABLE 2. Gene Expression Changes in Postmortem Male Schizophrenia Subjects and Neuroleptic-Treated Rats
Human Subjects

Animal Subjects
Haloperidol-Treated
Sprague-Dawley Rats
(N=16)

Schizophrenia Group (N=13)
Gene of Interest
GABAergic markers
GABAA-α6
GABAA-β3
GABAA-δ
GAD65
GAD67
GAT-1
PV mRNA
NMDA receptor subunits
NR1
NR2-A
NR2-B
NR2-C
NR2-D
Cerebellar neuromodulators
GluR6
KA2
mGluR2
mGluR3
Neuronal nitric oxidase
synthase

Change (%)a

F

df

Pairwise pb

+44
+16
+52
–26
–38
–43
–12

5.286
2.138
8.124
2.696
6.551
4.348
0.36

4, 21
4, 21
4, 21
4, 21
4, 21
4,21
4,21

0.005
0.12
0.0002
0.02
0.01
0.002
0.89

–5
–6
–16
+7
+6

0.476
1.037
3.942
0.978
0.78

4, 21
4, 21
4, 21
4, 21
4, 21

+23
+29
–27
–5
–28

4.353
7.722
4.418
1.871
2.65

4, 21
4, 21
4, 21
4, 21
4, 21

ANCOVA p Change (%)c

pd

Change (%)c

pd

+25
+35
+25
+28
+31
–23

<0.0001
<0.0001
<0.0001
0.002
<0.0001
<0.0001

0.004
0.1
<0.001
0.06
0.001
0.01
0.83

+29
+33
+4
–19
+20
+17

0.1
0.01
0.87
0.01
0.001
0.02

0.5
0.27
0.07
0.54
0.27

0.75
0.41
0.02
0.44
0.55

+13
+23
+34
–15
–49

0.04
0.08
0.18
0.28
<0.0001

+34
–24
–20
–19
–10

<0.0001
<0.0001
0.004
0.0005
0.1009

0.03
0.0002
0.002
0.54
0.03

0.01
0.001
0.01
0.2
0.06

+26
–10
+32

0.03
0.13
0.0008

0.0005
<0.0001
0.62

e

e

+24
–23
+10

+11

0.34

–19

0.02

e

e

a Change represents the percentage of gene expression alteration in schizophrenia subjects (versus nonpsychiatric
b Values determined using Wilcoxon Signed-Rank Test for matching pairs.
c Change represents the percentage of gene expression alteration in drug-treated rats (versus vehicle-treated rats).
d Values determined using Student’s t tests.
e Value not determined.

ine the nature and extent of GABA dysfunction in different
neuronal populations. Initial studies examined the expression of seven markers of GABA function in the lateral
cerebellar hemisphere of 13 pair-matched schizophrenia
and comparison subjects using real-time PCR. To normalize the levels of a specific mRNA, β-actin was utilized because the expression of this particular mRNA did not differ
between schizophrenia and comparison subjects (see the
figure in the data supplement accompanying the online
version of this article). Analysis of GABAergic transcript
levels in schizophrenia subjects and matched comparison
subjects using the Wilcoxon Signed-Rank Test revealed
significant decreases in mRNA levels of GAD67, GAD65 ,
and GAT-1 (schizophrenia to comparison group ratio=
0.62, 0.74, and 0.57, respectively). However, no decreases
in mRNA levels of parvalbumin were found (Table 2, Figure 1). Similar decreases in these transcripts were observed when cyclophilin was used as the housekeeping
gene (see the data supplement accompanying the online
version of this article). Subjects with schizophrenia also
showed significant increases in mRNA levels for the granule-cell extrasynaptic GABAA receptor subunits α6 (schizophrenia to comparison group ratio=1.44) and δ (schizophrenia to comparison group ratio=1.53) relative to βactin mRNA. However, no changes were found in GABAAβ3 mRNA, which is expressed in several cell types. In addition to pairwise analyses, we evaluated the effect of potential confounding variables, such as age, freezer storage

4
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Clozapine-Treated
Long-Evans Rats
(N=20)

e

e

e

e

comparison subjects).

time, and RNA integrity number, using ANCOVA. As detailed in Table 2, ANCOVA results confirmed that mRNA
levels of GAD67, GAT-1, GABAA-α6, and GABAA-δ were significantly different for schizophrenia subjects relative to
comparison subjects (p<0.05), while mRNA levels of
GAD65 were close to significant (p=0.06).
To examine possible gene-gene interactions, mRNA levels were analyzed using Spearman’s r correlations. In the
schizophrenia group, positive correlations were 1) GAD67
with GAD65 (r=0.922, p<0.001) and 2) GAT-1 (r=0.797, p=
0.001) and GAD65 with GAT-1 (r=0.770, p=0.002) (Figure 1).
Comparison subjects also showed a positive correlation
between GAD67 and GAT-1 (r=0.646, p=0.02).

NMDA Receptor Subunit Expression in the
Lateral Cerebellar Hemisphere of Schizophrenia
Subjects
In addition to GABA deficits, NMDA dysfunction has
been found in schizophrenia patients (28). In the present
study, analyses of the levels of NMDA receptor subunits
NR1, NR2-A, NR2-B, NR2-C, and NR2-D, using the Wilcoxon Signed-Rank Test, revealed no significant changes
except for a tendency toward decrease in the Golgi cell-selective subunit NR2-B (29) (schizophrenia to comparison
group ratio=0.84, p=0.07 [Table 2]). Furthermore, when
considering the effect of age, freezer storage time, and
RNA integrity number using ANCOVA, we found a significant decrease in the levels of NR2-B among schizophrenia
subjects (p=0.004 [Table 2]). In addition, the levels of NR2AJP In Advance
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FIGURE 1. GABAergic Marker Transcript Expression and Correlations in the Cerebellum of Postmortem Schizophrenia Subjects and Postmortem Interval-Matched Comparison Subjectsa
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A
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Rel. mRNA Levels

10.0
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GAD67

0

1

2

3

4
5
GAD67

6

7

GAT-1

4
3
2
1
0

0

1

2

3

4
5
GAD67

GABAA-β6

GABAA-α6

PV

7
6
5

4
3
2
1
0

a

B
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GAD65

7
6
5

GAT-1

GAD65

6

7

GABAA-δ

7
6
5
4
3
2
1
0

0

1

2

3

4
5
GAD65

6

7

The top row illustrates significant decreases seen in GABAergic marker transcript expression levels for GAD67 and GAT-1 and significant increases seen in GABAA-α6 and GABAA-δ among schizophrenia subjects (Wilcoxon Signed-Rank Test [see Table 2]). Expression levels are relative
to β-actin. Values show mRNA levels in matched pairs and averages for schizophrenia and comparison subjects. The bottom row illustrates
GABAergic marker transcript expression levels for GAD67, GAD65, and GAT-1, which are all significantly correlated using Spearman’s r correlation coefficient.

B in the schizophrenia group were positively correlated
with the levels of NR1 (r=0.553, p=0.05), NR2-A (r=0.553,
p=0.05), and NR2-D (r=0.663, p=0.01).

Cerebellar Neuromodulator Expression in the
Lateral Cerebellar Hemisphere of Schizophrenia
Subjects
GABA release onto cerebellar granule cells is regulated
at the cerebellar glomerulus, where pontine mossy fibers
and Golgi cells synapse onto granule-cell dendrites in a
close structural and functional unit. Thus, we examined
the major modulatory factors of this unit, which could
contribute to decreased GABA neurotransmission to granule cells. Of these modulatory factors, we observed significant decreases in GABAergic transcript levels of neuronal
nitric oxide synthase (schizophrenia to comparison group
ratio=0.72), present in granule cells and molecular layer
interneurons (30), and the Golgi cell-specific mGluR2 (31)
(schizophrenia to comparison group ratio=0.73) but not
mGluR3 (Figure 2). Interestingly, both nitric oxide production by neuronal nitric oxide synthase and presynaptic
mGluR2 receptor activation modulate GABA release from
Golgi cells (32). Moreover, we found significantly increased levels of the glutamatergic kainate receptor subunits GluR6 (schizophrenia to comparison group ratio=
1.23) and the granule cell-specific subunit KA2 (schizoAJP In Advance

phrenia to comparison group ratio=1.29 [33]). ANCOVA
revealed that all changes in GABAergic transcript levels
were significant (p<0.05) except for changes in neuronal
nitric oxide synthase, which were near significant (p=0.06
[Table 2]).

Correlations of Transcripts Levels in Golgi Cells,
Granule Cells, and Local Cerebellar Circuitry
Components
To further investigate the functional integrity of the cerebellar glomerulus in schizophrenia subjects, interactions
between specific markers in the Golgi-granule cell circuit
were analyzed. We found positive correlations for the
Golgi cell-selective NR2-B with GAD67 (r=0.922, p<0.001),
GAD65 (r=0.854, p<0.001), and GAT-1 (r=0.671, p=0.01) and
for mGluR2 with GAD65 (r=0.575, p=0.04), all of which
were decreased in the schizophrenia group. In addition,
GABAergic transcripts expressed in granule cells showed
correlations for NR2-C with GABAA-α6 (r=0.639, p=0.02),
GABAA-β3 (r=0.722, p=0.005), GABAA-δ (r=0.652, p=0.02),
and KA2 (r=0.726, p=0.005), which were all increased
among schizophrenia subjects. Finally, we found that neuronal nitric oxide synthase correlated with GABAA-β3 (r=
0.757, p=0.003); GABAA-α6 correlated with GluR6 (r=0.659,
p=0.01); and KA2 correlated with GABAA-δ (r=0.600, p=
0.03).
ajp.psychiatryonline.org
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FIGURE 2. Neuromodulator Transcript Expression and Golgi-Granule Cell-Circuit Correlations in the Cerebellum of Postmortem Schizophrenia Subjects and Postmortem Interval-Matched Comparison Subjectsa
A
12
Schizophrenia Patients
Comparison Subjects

Rel. mRNA Levels

10
8
6
4
2
0

a

1

2

3

4 5 6
mGluR2

7

8

9

9
8
7
6
5
4
3
2
1

1

2

3

4

5 6
NR2B

nNOS

mGluR3

nNOS

GluR6

GluR6

B
9
8
7
6
5
4
3
2
1

mGluR2

KA2

GluR6

7

8

9

9
8
7
6
5
4
3
2
1

1

2

3

4

5 6
NR2B

7

8

9

The top row illustrates significant increases seen in the levels of the kainate receptor subunits GluR6 and KA2 and significant decreases found
in levels of mGluR2 and neuronal nitric oxide synthase among schizophrenia subjects (Wilcoxon Signed-Rank Test [see Table 2]). Expression
levels are relative to β-actin. Values show mRNA levels in matched pairs and averages for schizophrenia and comparison subjects. The bottom
row illustrates the significant correlations between markers expressed in the Golgi-granule cell circuit (using Spearman’s r correlation coefficient).

Positive correlations for components of Golgi cell-granule cell circuitry were 1) NR2-B with GABAA-β3 (r=0.600, p=
0.03), GluR6 (r=0.594, p=0.03), and neuronal nitric oxide
synthase (r=0.624, p=0.02) and 2) mGluR2 with GluR6 (r=
0.713, p=0.006) and GABAA-α6 (r=0.797, p<0.001). Significant negative correlations were observed for GAT-1 with
NR2-C (r=–0.553, p=0.05) and KA2 (r=–0.779, p=0.002),
presumably reflecting a compensatory mechanism to increase GABA neurotransmission in the synaptic cleft.

Medication Effects on Gene Expression in
Haloperidol- and Clozapine-Treated Rats
Both schizophrenia and comparison subjects were receiving antipsychotics at the time of death, with approximately one-half of the schizophrenia group being treated
with typical antipsychotics and one-half being treated
with atypical antipsychotics (Table 1). Analysis of gene expression levels between schizophrenia subjects who were
receiving atypical versus typical antipsychotics showed a
significant increase in GAD 67 gene expression for the
former (p=0.03 [Mann-Whitney Rank Sum Test]). This
finding suggests that medication type may have an effect
on gene expression levels in individuals with schizophrenia. Therefore, we analyzed the levels of the same mRNAs
in the cerebellum of rats chronically treated with approxi-

6

ajp.psychiatryonline.org

mately 1 mg/kg/day of the typical neuroleptic haloperidol. As detailed in Table 2, we found significant increases
in GABAA-β3, GAD67, GAT-1, NR1, GluR6, and mGluR2 in
these rats. However, a significant decrease was seen in the
expression of GAD65 and NR2-D transcripts.
To examine the effects of atypical antipsychotics, rats
were treated with clozapine for 21 days (10 mg/kg/day). As
detailed in Table 2, these animals expressed increased
mRNA levels of GABAA-β3, GAD67, and GAD65, while GAT-1
expression was significantly decreased. The NMDA receptor subunit NR1 was significantly increased, whereas NR2A, NR2-B, and NR2-C were all decreased. Finally, GluR6
was significantly increased, KA2 and neuronal nitric oxide
synthase were decreased by clozapine treatment. Overall,
our results indicate that clozapine could compensate, in
part, for the decreased level of GABA synthesizing enzymes and other gene expression changes observed in
schizophrenia subjects.

Discussion
An increasing number of studies support the hypothesis
that GABA neurotransmission is deficient in individuals
with schizophrenia (2–4). Although GABAergic deficits
have been well characterized in the prefrontal cortex (5–7)
AJP In Advance
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FIGURE 3. Gene Alterations in the Cerebellum of Postmortem Schizophrenia Subjects and Postmortem Interval-Matched
Comparison Subjectsa
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The graph illustrates decreased GABA gene expression in Golgi cells and concomitant increases in granule-cell gene expression. Expression
patterns are based on the Allen Brain Atlas (www.brain-map.org) and data from the literature. PV=parvalbumin; GrC=granule cells; GoC=
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and limbic system (8, 9), few studies have examined these
deficits in the cerebellum (10, 11). The present study demonstrated GABA transmission deficits in the lateral cerebellar hemisphere in individuals with schizophrenia,
which implicates selective impairment in local granulecell Golgi-cell communication, along with altered expression of neuromodulators of granule cell activity. Disinhibition of granule cells by deficient tonic inhibition from
Golgi cells could disrupt cerebellar output by Purkinje
cells, which in turn may affect other brain regions in the
cortico-cerebellar-thalamic-cortical circuit, including the
prefrontal cortex (34).
Several discrete GABAergic interneurons are located in
the cerebellum, most notably Golgi cells in the granule
layer and basket and stellate cells in the molecular layer.
Although basket and stellate cells provide feed-forward inhibition from granule cells to Purkinje cells, Golgi cells
AJP In Advance

provide the sole source of feedback inhibition to granule
cells (35). All of these interneurons express the GABA synthesizing enzymes GAD65 and GAD67. Our findings indicate that the levels of these GABAergic transcripts are decreased in individuals with schizophrenia relative to
comparison subjects, suggesting that GABA synthesis may
be impaired in schizophrenia patients. Consistent with
our findings, Fatemi et al. (11) reported decreases in protein levels of both GAD65 and GAD67 in the cerebellum of a
separate cohort of schizophrenia subjects.
Although GABA synthesis cannot be directly measured
in postmortem tissue, other markers can be investigated
to infer whether GABAergic transmission is reduced. For
example, decreased levels of the presynaptic GAT-1 may
reflect a compensatory attempt to increase synaptic
GABA. Mature Golgi and basket/stellate cells express GAT1, while Purkinje cells and glia do not (36), suggesting that
ajp.psychiatryonline.org
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GAT-1 deficits may be restricted to specific GABAergic interneurons. This is consistent with a similar decrease in
GAT-1 observed in the prefrontal cortex of schizophrenia
patients in association with GAD67 deficits (12). Interestingly, the calcium binding protein parvalbumin, which
has been found to be decreased in the prefrontal cortex in
individuals with schizophrenia (6), was not decreased in
the present study, suggesting that different subtypes of interneurons may be affected in the cerebellum. Parvalbumin is expressed primarily in Purkinje and basket/stellate
cells but only in a small subpopulation of Golgi cells (37).
Conversely, the significant increases in the expression of
the extrasynaptic GABAA receptor subunits α6 and δ suggest that a compensatory mechanism may occur in order
to increase GABA receptivity by granule cells. As a result of
freezing the tissue samples, we were unable to confirm the
localization of specific transcripts by in situ hybridization.
However, our findings point to Golgi cells as the predominately affected cerebellar interneuron in schizophrenia.
A competing, but not mutually exclusive, hypothesis for
schizophrenia proposes that NMDA receptor-mediated
neurotransmission may be deficient in individuals with
schizophrenia (28) and that GABAergic interneurons are
particularly vulnerable to NMDA receptor hypofunction
(38). In the present study, GABAergic interneuron function
in the cerebellum was further investigated by measuring
the expression of cell-selective NMDA receptor subunits.
Although each cell type expresses the obligatory NR1 subunit, Purkinje cells express primarily NR2-A; Golgi cells express primarily NR2-B; granule cells express primarily
NR2-C; and basket/stellate cells express primarily NR2-D
(29). Among these subunits, we found a decrease in the
levels of the Golgi cell-selective NR2-B. The strong correlations between NR2-B expression and GAD67, GAD65, and
GAT-1 expression in the schizophrenia group further suggests that GABA transmission deficits may be localized to
Golgi cells. Alternatively, it is possible that the number of
Golgi cells and not their activity may be decreased in individuals with schizophrenia.
GABA release by Golgi cells is regulated by various factors in both Golgi and granule cells, including Golgi cellspecific mGluR2 (31) and the granule cell-located neuronal nitric oxide synthase (32). Activation of both systems
normally decreases GABA release by Golgi cells, and both
were decreased in our cohort of schizophrenia subjects
(Figure 2), presumably compensating for decreased levels
of GABA in the synapse. On the other hand, mGluR3,
which is expressed in Golgi cells and glia (31), was not altered in the schizophrenia group. In addition, although
decreased levels of mRNA in the receptor subunits GluR6
and KA2 have been previously reported in the prefrontal
cortex and hippocampus of schizophrenia patients (33,
39), we observed increased cerebellar expression of these
kainate receptors. Since both markers are expressed in
granule cells and these cells have shown increased expression of activity dependent-genes in the same group of
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schizophrenia subjects (24), it is possible that the changes
in kainate receptor subunits may reflect a change in basal
granule cell activity.
The changes in gene expression and putative cerebellar
microcircuit alterations are illustrated in Figure 3. Although postmortem human tissue studies only provide a
limited view of the premortem state and the use of tissue
homogenates does not allow localization of transcripts to
specific cell types, analyses of gene expression patterns
using gene-gene correlations are valuable tools to infer the
functional relevance of the observed changes across different cells in the network. An alteration in GABA neurotransmission between Golgi and granule cells is further
evidenced by the positive correlations between the modulators of GABA release neuronal nitric oxide synthase and
mGluR2 and between the Golgi specific marker NR2-B
and neuronal nitric oxide synthase. Moreover, the negative correlations for GAT-1 with the granule cell-specific
receptor subunits NR2-C and KA2 suggest a defect in
modulation of GABA release by Golgi cells and increased
granule cell firing. Although these findings are intriguing,
animal models will need to be developed in order to confirm the dynamic nature of the interactions between granule cell and Golgi cell gene-expression patterns reported
in the present study.
Our gene expression findings in schizophrenia subjects
point to dysfunctional regulation of GABA release between
Golgi and granule cells but do not take into account any effects of antipsychotic medication. Although antipsychotics
have been shown to affect gene expression in several brain
regions, these alterations have not been demonstrated in
the cerebellum. As detailed in Table 2, haloperidol treatment resulted in increased levels of GAD67, mGluR2, NR2B, GAT-1, and neuronal nitric oxide synthase in chronically
treated rats, whereas clozapine was more effective in increasing the expression of GAD67 and GAD65. Comparison
of the levels of GluR6, GABAA-α6, and GABAA-δ receptor
mRNAs in schizophrenia subjects and treated animals suggests that the observed increases of these transcripts in the
schizophrenia group could be explained by medication effects. In contrast, the increases in KA2 mRNA seen in the
schizophrenia group could not be attributable to antipsychotic treatment, since both haloperidol and clozapine decreased the levels of KA2 mRNA. In addition, medication
effects could account for an underrepresentation of the
changes in NR2-C and NR2-D gene expression in the
schizophrenia group. Based on the results of the chronic
neuroleptic exposure in rats, haloperidol seems to have a
more beneficial effect on gene expression in the local cerebellar circuit relative to clozapine. Furthermore, although
both medications were effective in increasing GAD67 expression in rats, neither treatment was effective in schizophrenia subjects. Our results support the idea that combining different types of antipsychotics with GABA A
receptor agonists may provide enhanced benefits for treatAJP In Advance
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ing the underlying GABA-glutamate pathophysiology of
schizophrenia.
In summary, we found that the expression of multiple
GABAergic markers is decreased in the lateral cerebellar
hemisphere among individuals with schizophrenia and
this deficit is most likely localized to Golgi cells. Overall,
patient mRNA expression data suggest that GABA neurotransmission deficits could be responsible for increased
granule cell activity and disinhibition of glutamatergic signaling in the cerebellum, leading to aberrant cerebellar
output. These changes may underlie not only the alterations in cerebellar blood flow observed in our schizophrenia cohort, but also, and most importantly, the clinical symptoms associated with abnormal cerebellar
function in schizophrenia (40).
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